The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring
Open accessAbstract
Doxorubicin (DOX) is one of the most effective anticancer drugs to treat various forms of cancers; however, its therapeutic utility is severely limited by its associated cardiotoxicity. Despite the enormous amount of research conducted in this area, the exact molecular mechanisms underlying DOX toxic effects on the heart are still an area that warrants further investigations. In this study, we reviewed literature to gather the best-known molecular pathways related to DOX-induced cardiotoxicity (DIC). They include mechanisms dependent on mitochondrial dysfunction such as DOX influence on the mitochondrial electron transport chain, redox cycling, oxidative stress, calcium dysregulation, and apoptosis pathways. Furthermore, we discuss the existing strategies to prevent and/or alleviate DIC along with various techniques available for therapeutic drug monitoring (TDM) in cancer patients treated with DOX. Finally, we propose a stepwise flowchart for TDM of DOX and present our perspective at curtailing this deleterious side effect of DOX.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,465
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Adriamycin: A New Anticancer Drug with Significant Clinical Activity
BLUM, R. H., & CARTER, S. K. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-2-249 · Cited by 1,057
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
The biosynthesis and functional role of cardiolipin
Schlame, M., Rua, D., & Greenberg, M. L. (2000) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00005-9 · Cited by 810
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Overview of Therapeutic Drug Monitoring
Kang, J.-S., & Lee, M.-H. (2009) · The Korean journal of internal medicine · doi:10.3904/kjim.2009.24.1.1 · Cited by 669
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A. (2000) · Annals of Oncology · doi:10.1023/a:1008365716693 · Cited by 618
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
BOHM, F., & PERNOW, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.06.004 · Cited by 516
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
Arola, O., Saraste, A., Pulkki, K. J., Kallajoki, M. A., Parvinen, M., & Voipio-Pulkki, L. M. (2000) · PubMed · Cited by 494
Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide
Mizutani, H., Tada-Oikawa, S., Hiraku, Y., Kojima, M., & Kawanishi, S. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.05.040 · Cited by 472
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., & Gabizon, A. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z · Cited by 385
Zhao, L., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep44735 · Cited by 375
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.
Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3585 · Cited by 357
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
Kaya, M. G., Ozkan, M., Gunebakmaz, O., Akkaya, H., Kaya, E. G., Akpek, M., Kalay, N., Dikilitas, M., Yarlioglues, M., Karaca, H., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.023 · Cited by 325
Doxorubicin induced heart failure: Phenotype and molecular mechanisms
Mitry, M. A., & Edwards, J. G. (2016) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2015.11.004 · Cited by 311
Spallarossa, P., Garibaldi, S., Altieri, P., Fabbi, P., Manca, V., Nasti, S., Rossettin, P., Ghigliotti, G., Ballestrero, A., & Patrone, F. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.024 · Cited by 294
Greene, R. F., Collins, J. M., Jenkins, J., Speyer, J. L., & Myers, C. E. (1983) · PubMed · Cited by 292
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995) · Circulation · doi:10.1161/01.cir.91.1.10 · Cited by 285
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Siveski-Iliskovic, N., Kaul, N., & Singal, P. K. (1994) · Circulation · doi:10.1161/01.cir.89.6.2829 · Cited by 265
Capranico, G., Tinelli, S., Austin, C. A., Fisher, M. L., & Zunino, F. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90050-a · Cited by 258
Liu, J., Mao, W., Ding, B., & Liang, C.-S. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00407.2008 · Cited by 255
Lissoni, P., Barni, S., Mandalà, M., Ardizzoia, A., Paolorossi, F., Vaghi, M., Longarini, R., Malugani, F., & Tancini, G. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00159-8 · Cited by 253
Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms
Rochette, L., Guenancia, C., Gudjoncik, A., Hachet, O., Zeller, M., Cottin, Y., & Vergely, C. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.005 · Cited by 248
Analysis of apoptosis by cytometry using TUNEL assay
Darzynkiewicz, Z., Galkowski, D., & Zhao, H. (2008) · Methods · doi:10.1016/j.ymeth.2007.11.008 · Cited by 247
Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.
Doroshow, J. H., Locker, G. Y., Ifrim, I., & Myers, C. E. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110328 · Cited by 245
Berry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B., Patek, A., & Martin, F. J. (1998) · Annals of Oncology · doi:10.1023/a:1008216430806 · Cited by 241
Weinstein, D. M., Mihm, M. J., & Bauer, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39082-2 · Cited by 229
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227
Wexler, L. H., Andrich, M. P., Venzon, D., Berg, S. L., Weaver-McClure, L., Chen, C. C., Dilsizian, V, Avila, N., Jarosinski, P., Balis, F. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.362 · Cited by 224
Fas-Mediated Apoptosis in Adriamycin-Induced Cardiomyopathy in Rats: In Vivo Study
Nakamura, T., Ueda, Y., Juan, Y., Katsuda, S., Takahashi, H., & Koh, E. (2000) · Circulation · doi:10.1161/01.cir.102.5.572 · Cited by 223
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0008-2 · Cited by 221
Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal Doxorubicin
Lotem, M., Hubert, A., Lyass, O., Goldenhersh, M. A., Ingber, A., Peretz, T., & Gabizon, A. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.12.1475 · Cited by 219
TORTI, F. M., BRISTOW, M. R., HOWES, A. E., ASTON, D., STOCKDALE, F. E., CARTER, S. K., KOHLER, M., BROWN, B. W., & BILLINGHAM, M. E. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-6-745 · Cited by 215
Kalivendi, S. V., Konorev, E. A., Cunningham, S., Vanamala, S. K., Kaji, E. H., Joseph, J., & Kalyanaraman, B. (2005) · Biochemical Journal · doi:10.1042/bj20050285 · Cited by 205
Dexrazoxane: A Review of its Use for Cardioprotection During Anthracycline Chemotherapy
Cvetkovi??, R. S., & Scott, L. J. (2005) · Drugs · doi:10.2165/00003495-200565070-00008 · Cited by 203
Structure of the adriamycin-cardiolipin complex
Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., & Ruysschaert, J.-M. (1990) · Biophysical Chemistry · doi:10.1016/0301-4622(90)80012-v · Cited by 200
Hortobagyi, G. N., Frye, D., Buzdar, A. U., Ewer, M. S., Fraschini, G., Hug, V., Ames, F., Montague, E., Carrasco, C. H., Mackay, B., et al. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z · Cited by 198
Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy
Li, L., Takemura, G., Li, Y., Miyata, S., Esaki, M., Okada, H., Kanamori, H., Khai, N. C., Maruyama, R., Ogino, A., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.568402 · Cited by 197
Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
Herman, E., Rahman, A., Ferrans, V. J., Vick, J., & Schein, P. (1983) · PubMed · Cited by 179
Govender, J., Loos, B., Marais, E., & Engelbrecht, A. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12176 · Cited by 176
Licata, S., Saponiero, A., Mordente, A., & Minotti, G. (2000) · Chemical Research in Toxicology · doi:10.1021/tx000013q · Cited by 176
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-842 · Cited by 176
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174
Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.
Forssen, E. A., & Tökés, Z. A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1873 · Cited by 171
Goorin, A. M., Chauvenet, A. R., Perez-Atayde, A. R., Cruz, J., McKone, R., & Lipshultz, S. E. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81668-3 · Cited by 163
Wei, Y., Gao, L., Wang, L., Shi, L., Wei, E., Zhou, B., Zhou, L., & Ge, B. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1309475 · Cited by 162
Tahover, E., Patil, Y. P., & Gabizon, A. A. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000182 · Cited by 160
Apoptosis in Adriamycin Cardiomyopathy and Its Modulation by Probucol
Kumar, D., Kirshenbaum, L. A., Li, T., Danelisen, I., & Singal, P. K. (2001) · Antioxidants & Redox Signaling · doi:10.1089/152308601750100641 · Cited by 159
Melatonin as an effective protector against doxorubicin-induced cardiotoxicity
Liu, X., Chen, Z., Chua, C. C., Ma, Y.-S., Youngberg, G. A., Hamdy, R., & Chua, B. H. L. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01023.2001 · Cited by 159
Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
Herman, E. H., Lipshultz, S. E., Rifai, N., Zhang, J., Papoian, T., YU, Z., Takeda, K., & Ferrans, V. J. (1998) · PubMed · Cited by 151
Marcillat, O., Zhang, Y., & Davies, K. J. A. (1989) · Biochemical Journal · doi:10.1042/bj2590181 · Cited by 149
Cardiotoxicity of doxorubicin and other anthracycline derivatives
Jain, D. (2000) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2000.103324 · Cited by 149
Sahu, B. D., Kumar, J. M., Kuncha, M., Borkar, R. M., Srinivas, R., & Sistla, R. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.11.018 · Cited by 141
López, M., Vici, P., Lauro, K. D., Conti, F., Paoletti, G., Ferraironi, A., Sciuto, R., Giannarelli, D., & MAINI, C. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.86 · Cited by 140
Sag, C. M., Köhler, A. C., Anderson, M. E., Backs, J., & Maier, L. S. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.07.016 · Cited by 139
Daugaard, G., Lassen, U., Bie, P., et al. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.03.009 · Cited by 139
Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
Franco, Y. L., Vaidya, T. R., & Ait‐Oudhia, S. (2018) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s170239 · Cited by 137
Self-citationLebrecht, D., Geist, A., Ketelsen, U., Haberstroh, J., Setzer, B., & Walker, U. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707294 · Cited by 136
Pointon, A., Walker, T. M., Phillips, K. M., Luo, J., Riley, J., Zhang, S., Parry, J. D., Lyon, J. J., Marczylo, E. L., & Gant, T. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012733 · Cited by 133
Smoluk, G. D., Fahey, R. C., Calabro-Jones, P. M., Aguilera, J. A., & Ward, J. F. (1988) · PubMed · Cited by 131
Akolkar, G., Dias, D. D. S., Ayyappan, P., Bagchi, A. K., Jassal, D. S., Salemi, V. M. C., Irigoyen, M. C., Angelis, K. D., & Singal, P. K. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00253.2017 · Cited by 131
Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., & Sakurai, M. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1155 · Cited by 130
Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model
Panjrath, G. S., Patel, V., Valdiviezo, C., Narula, N., Narula, J., & Jain, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.060 · Cited by 126
Herman, E., Ferrans, V. J., Myers, C. E., & Vleet, J. F. V. (1985) · PubMed · Cited by 120
Herman, E. H., Zhang, J., Chadwick, D. P., & Ferrans, V. J. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050048 · Cited by 117
Kim, K.-H., Oudit, G. Y., & Backx, P. H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125773 · Cited by 115
Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity
de Geus‐Oei, L., Mavinkurve‐Groothuis, A. M. C., Bellersen, L., Gotthardt, M., Oyen, W. J. G., Kapusta, L., & van Laarhoven, H. W. M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.082784 · Cited by 113
The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy
Bien, S., Riad, A., Ritter, C. A., Gratz, M., Olshausen, F., Westermann, D., Grube, M., Krieg, T., Ciecholewski, S., Felix, S. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1344 · Cited by 111
Anthracycline cardiotoxicity in long-term survivors of childhood cancer
Scully, R. E., & Lipshultz, S. E. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0006-4 · Cited by 109
Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats
Swamy, A. H. V., Wangikar, U., Koti, B., Thippeswamy, A. H. M., Ronad, P. M., & Manjula, D. V. (2011) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.84952 · Cited by 102
Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity
Nabati, M., Janbabai, G., Baghyari, S., Esmaili, K., & Charati, J. Y. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000470 · Cited by 101
Priya, L. B., Baskaran, R., Huang, C., & Padma, V. V. (2017) · Scientific Reports · doi:10.1038/s41598-017-12060-9 · Cited by 101
Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
Legha, S. S., Benjamin, R. S., Mackay, B., Yap, H. Y., Wallace, S., Ewer, M. S., Blumenschein, G. R., & Freireich, E. J. (1982) · Cancer · Cited by 94
Increased Plasma Endothelin-1 and Cardiac Nitric Oxide during Doxorubicin-Induced Cardiomyopathy
Sayed‐Ahmed, M. M., Khattab, M. M., Gad, M. Z., & Osman, A. M. (2001) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2001.d01-148.x · Cited by 91
Cui, L., Guo, J., Zhang, Q., Yin, J., Li, J., Zhou, W. J., Zhang, T., Yuan, H., Zhao, J., Zhang, L., et al. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.04.018 · Cited by 91
Mechanism of inhibition of mitochondrial enzymatic complex I–III by adriamycin derivatives
Goormaghtigh, E., Huart, P., Brasseur, R., & Ruysschaert, J. (1986) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(86)90406-2 · Cited by 89
Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
Bennink, R. J., van den Hoff, M. J. B., van Hemert, F. J., de Bruin, K. M., Spijkerboer, A. L., Vanderheyden, J., Steinmetz, N. D., & van Eck‐Smit, B. L. F. (2004) · PubMed · Cited by 85
Yu, X., Cui, L.-B., Zhang, Z., Zhao, Q., & Li, S. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt082 · Cited by 84
The Cardioprotective Role of Probucol Against Anthracycline and Trastuzumab-Mediated Cardiotoxicity
Walker, J. R., Sharma, A. K., Lytwyn, M., Bohonis, S., Thliveris, J. A., Singal, P. K., & Jassal, D. S. (2011) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2011.01.018 · Cited by 81
Troponin-T and Brain Natriuretic Peptide as Predictors for Adriamycin-Induced Cardiomyopathy in Rats
Koh, E., Nakamura, T., & Takahashi, H. (2004) · Circulation Journal · doi:10.1253/circj.68.163 · Cited by 79
Othman, A. I., El-Missiry, M. A., Amer, M. A., & Arafa, M. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.08.004 · Cited by 78
Liu, T.-J., Yeh, Y., Ting, C.-T., Lee, W.-L., Wang, L.-C., Lee, H.-W., Wang, K.-Y., Lai, H., & Lai, H. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn192 · Cited by 76
Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin
Kısmet, E., Varan, A., Ayabakan, C., et al. (2003) · Pediatric Blood & Cancer · doi:10.1002/pbc.10368 · Cited by 75
Mitochondrial membrane modifications induced by adriamycin-mediated electron transport
Goormaghtigh, E., Pollakis, G., & Ruysschaert, J. M. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90593-2 · Cited by 74
Kanter, P. M., Bullard, G. A., Ginsberg, R., Pilkiewicz, F. G., Mayer, L. D., Cullis, P. R., & Pavelic, Z. P. (1993) · PubMed · Cited by 74
ABDEL-WAHAB, M. H., Akoul, E.-S. E. M. S., & Abdel‐Aziz, A. H. (2000) · Tumori Journal · doi:10.1177/030089160008600210 · Cited by 70
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H., & Kremer, L. C. M. (2005) · doi:10.1002/14651858.cd003917.pub2 · Cited by 70
Kanter, P. M., Bullard, G. A., Pilkiewicz, F. G., Mayer, L. D., Cullis, P. R., & Pavelic, Z. P. (1993) · PubMed · Cited by 68
Popelová, O., Štěrba, M., Hašková, P., Šimůnek, T., Hroch, M., Gunčová, I., Nachtigal, P., Adamcová, M., Geršl, V., & Mazurová, Y. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605192 · Cited by 61
Cytofluorescence detection of adriamycin-mitochondria interactions in isolated, perfused rat heart
Nicolay, K., Fok, J. J., Voorhout, W. F., Post, J. A., & KRUIJFF, B. D. (1986) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(86)90119-9 · Cited by 61
Lüdke, A., Akolkar, G., Ayyappan, P., Sharma, A. K., & Singal, P. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179452 · Cited by 60
Moreira, A. C., Branco, A. F., Sampaio, S. F., Cunha‐Oliveira, T., Martins, T. R., Holy, J. M., Oliveira, P. J., & Sardão, V. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.015 · Cited by 59
Amifostine protection against doxorubicin cardiotoxicity in rats
Dragojevic-Simic, V. M., Dobrić, S., Bokonjić, D., Vučinić, Ž., Sinovec, S. M., Jacevic, V. M., & Dogovic, N. P. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200402000-00011 · Cited by 58
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
Jones, R. L. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1311 · Cited by 56
Shoukry, H. S., Ammar, H. I., Rashed, L. A., Zickri, M. B., Shamaa, A., Elfadl, S. A., Abu‐El‐Rub, E., Sekaran, S., & Dhingra, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181535 · Cited by 53
Progression of excitation-contraction coupling defects in doxorubicin cardiotoxicity
Llach, A., Mazevet, M., Matéo, P., Villejoubert, O., Ridoux, A., Rücker‐Martin, C., Ribeiro, M., Fischmeister, R., Crozatier, B., Bénitah, J., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.11.019 · Cited by 53
Agustini, F. D., Arozal, W., Louisa, M., Siswanto, S., Soetikno, V., Nafrialdi, N., & Suyatna, F. D. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1073750 · Cited by 51
Pacciarini, M. A., Barbieri, B., Colombo, T., Broggini, M., Garattini, S. K., & Donelli, M. G. (1978) · PubMed · Cited by 50
Detection and characterization of translational research in cancer and cardiovascular medicine
Jones, D. S., Cambrosio, A., & Mogoutov, A. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-57 · Cited by 48
Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity
Nazeyrollas, P., Prevost, A. T., Baccard, N., et al. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050888 · Cited by 47
Topoisomerase IIα-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin
Yan, T., Deng, S., Metzger, A., Gödtel‐Armbrust, U., Porter, A. C. G., & Wojnowski, L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0139 · Cited by 46
Coordinated Upregulation of the Cardiac Endothelin System in a Rat Model of Heart Failure
Picard, P., Smith, P., Monge, J. C., Rouleau, J. L., Nguyen, Q. T., Calderone, A., & Stewart, D. J. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199800001-00082 · Cited by 44
Delemasure, S., Vergely, C., Zeller, M., Cottin, Y., & Rochette, L. (2006) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2006.02.005 · Cited by 44
Lebrecht, D., Kirschner, J., Geist, A., Haberstroh, J., & Walker, U. A. (2009) · Cardiovascular Pathology · doi:10.1016/j.carpath.2009.06.006 · Cited by 42
Saleem, M. T. S., Chetty, M. C., & Kavimani, S. (2014) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944713516532 · Cited by 42
Gao, J., Chen, T., Zhao, D., Zheng, J., & Liu, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168219 · Cited by 42
Subcellular basis of vitamin C protection against doxorubicin-induced changes in rat cardiomyocytes
Lüdke, A., Sharma, A. K., Bagchi, A. K., & Singal, P. K. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1059-z · Cited by 41
Erythropoietin protects against doxorubicin-induced heart failure
Ammar, H. I., Saba, S., Ammar, R. I., El-Sayed, L., Ghaly, W. B. A.-A., & Dhingra, S. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2010 · Cited by 38
Mazzucchelli, S., Ravelli, A., Gigli, F., Minoli, M., Corsi, F., Ciuffreda, P., & Ottria, R. (2016) · Biomedical Chromatography · doi:10.1002/bmc.3863 · Cited by 37
de Oliveira, B. L., & Niederer, S. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005214 · Cited by 37
Allen, S. A., Rednour, S., Shepard, S., & Pond, B. B. (2017) · Biomedical Chromatography · doi:10.1002/bmc.3998 · Cited by 35
Schwebe, M., Ameling, S., Hammer, E., Monzel, J. V., Bonitz, K., Budde, S., Schult, K., Oswald, S., Scheuch, E., Grube, M., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.01.014 · Cited by 34
Chan, K. Y. Y., Xiang, P., Zhou, L., Li, K., Ng, P.-C., Wang, C. C., Zhang, L., Deng, H., Pong, N. H., Zhao, H., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr001 · Cited by 32
The effects of mangiferin (Mangifera indica L) in doxorubicin-induced cardiotoxicity in rats
Arozal, W., Suyatna, F., Juniantito, V., Rosdiana, D., Amurugam, S., Aulia, R., Monayo, E., & Siswandi, R. (2014) · Drug Research · doi:10.1055/s-0034-1394457 · Cited by 32
Integrative view on how erythropoietin signaling controls transcription patterns in erythroid cells
Perreault, A. A., & Venters, B. J. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000415 · Cited by 32
N -Acetylcysteine prevents doxorubucine-induced cardiotoxicity in rats
Arıca, V., Demir, I. H., Tutanç, M., Başarslan, F., Arica, S. G., Karcıoğlu, M., Oztürk, H. O., & Nacar, A. (2013) · Human & Experimental Toxicology · doi:10.1177/0960327112467043 · Cited by 28
Jo, S., Kim, L. S., Kim, S., Kim, H., Han, S.-J., Park, W. J., & Choi, Y. J. (2013) · Korean Circulation Journal · doi:10.4070/kcj.2013.43.3.174 · Cited by 27
Pendlebury, A., Debernardo, R. L., & Rose, P. G. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000521 · Cited by 16
Kayser, K., Kayser, G., André, S., Altiner, M., & Gabius, H. (1999) · Oncology Reports · doi:10.3892/or.6.5.1153 · Cited by 3
[123I-MIBG scintigraphy in cardiotoxicity related to antineoplastic agents].
Ono, M., & Takahashi, T. (1994) · PubMed · Cited by 3
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Christidi, E., & Brunham, L. R. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03614-x · Cited by 684
Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches
Sheibani, M., Azizi, Y., Shayan, M., Nezamoleslami, S., Eslami, F., Farjoo, M. H., & Dehpour, A. R. (2022) · Cardiovascular Toxicology · doi:10.1007/s12012-022-09721-1 · Cited by 276
Wu, L., Wang, L., Du, Y., Zhang, Y., & Ren, J. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.10.003 · Cited by 257
Wang, J., Li, M., Jin, L., Guo, P., Zhang, Z., Zhanghuang, C., Tan, X., Mi, T., Liu, J., Wu, X., et al. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2141921 · Cited by 60
Metadata
- Authors
- Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 96
- Issue
- 2
- Pages
- 219-232
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2948077402
- Cited by
- 334
- References
- 145
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.